Mutant KRAS and GATA6 Stratify Survival in Patients Treated with Chemotherapy for Pancreatic Adenocarcinoma: A Prospective Cohort Study
Plasma mutant <i>KRAS</i> ctDNA concentrations and GATA6 expression could serve as significant prognostic biomarkers in patients with PA, potentially guiding therapeutic decisions and prognostication.
Authors
- Nayoung Han (ORCID: https://orcid.org/0000-0001-8710-4280)
- Soobeen Heo
- Sang Myung Woo (ORCID: https://orcid.org/0000-0003-3786-4403)
- Hyeong Min Park (ORCID: https://orcid.org/0000-0002-7579-0241)
- Mi Rim Lee
- Jung Won Chun (ORCID: https://orcid.org/0000-0003-1964-7501)
- Hyeji Kim (ORCID: https://orcid.org/0000-0002-2256-5729)
- Dong-eun Lee (ORCID: https://orcid.org/0000-0002-8342-4081)
- Sun‐Young Kong (ORCID: https://orcid.org/0000-0003-0620-4058)
- Woo Jin Lee (ORCID: https://orcid.org/0000-0003-2115-6701)
- Tae Hyun Kim (ORCID: https://orcid.org/0000-0001-8413-3385)
- Yun‐Hee Kim (ORCID: https://orcid.org/0000-0001-7571-9958)
- Sung-Sik Han
- Sang-Jae Park
Institutions
- National Cancer Center (KR)
Publication Details
- Journal
- Cancers
- Published
- 2025-03-05
- DOI
- https://doi.org/10.3390/cancers17050896
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Center